Expiration Date: February 22, 2017
Media: Print with online posttest, evaluation, and request for credit
Overview
This activity is designed to inform physicians about the latest treatment advances in early-stage and metastatic breast cancer, including approved and investigational management strategies.
Instructions For This Activity & Receiving Credit
|
Target Audience
This activity is directed toward medical oncologists, primary care physicians, nurses, and nurse practitioners who treat patients with breast cancer. Surgical oncologists, radiation oncologists, pathologists, gynecologists, fellows, physician assistants, and other healthcare providers interested in the management of breast cancer are also invited to participate.
Learning Objectives
After participating in this CME activity, learners should be better prepared to:
- Explain the rationale and appropriate place for vaccines in the treatment of breast cancer
- Discuss the role of checkpoint blockade in the treatment of breast cancer
- Summarize data from recent trials of vaccines and immunotherapies in breast cancer
- Describe some of the combination therapies currently being studied in breast cancer
- Discuss issues involved in matching patients with appropriate treatments for breast cancer
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and Novartis.
Faculty
Elizabeth Mittendorf, MD, PhD Associate Professor
Department of Breast Surgical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support: Galena Biopharma and Antigen Express (institution receives funding)
Accreditation/Designation of Credit Statement
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC. Contact information for questions about the activity.
Hardware And Software Requirements
Supported BrowsersInternet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
- A PowerPC processor-based Macintosh computer
- At least 64MB of RAM
- Mac OS 7.5 or later
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise